Glucosio Galenica Senese

Glucosio Galenica Senese is a sterile solution for injection that contains glucose monohydrate as the sole active ingredient. The product is supplied in an unspecified strength and is intended for intravenous administration. Manufactured in the European Union, it is classified as an excipient/solvent used in parenteral nutrition and fluid replacement. The solution provides a direct source of glucose for patients requiring intravenous energy support therapy.

Glucosio Galenica Senese is employed in clinical settings where rapid glucose delivery and fluid balance are required.

- Management of hypoglycemia when oral intake is not feasible. - Component of total parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in peri‑operative or trauma care. - Support for patients with metabolic disorders that limit endogenous glucose production. - Adjunct in drug dilution for intravenous infusion when a glucose carrier is needed.

Intravenous administration of glucose monohydrate can be associated with a range of observed effects, most of which are related to the metabolic and osmotic properties of the solution.

Common: - Transient hyperglycemia that resolves as glucose is metabolized. - Mild irritation at the injection site or peripheral vein. - Electrolyte shifts, particularly a temporary decrease in serum potassium. - Fluid overload in patients with compromised cardiac function.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypotension from rapid infusion of large volumes. - Acute metabolic acidosis in patients with impaired lactate clearance.

When using Glucosio Galenica Senese, clinicians should observe several precautionary measures to minimise risks and ensure appropriate patient monitoring.

- Verify blood glucose level before and after infusion. - Adjust infusion rate in patients with heart failure or renal insufficiency. - Use aseptic technique to prevent catheter‑related infections. - Monitor electrolytes, especially potassium and sodium, during therapy. - Avoid administration to patients with known hypersensitivity to glucose solutions. - Consider compatibility with other intravenous drugs before co‑infusion.

Glucose monohydrate solutions may interact with other intravenously administered agents, influencing their efficacy or safety profile.

Avoid: - Co‑administration with high‑dose insulin without glucose monitoring. - Simultaneous infusion of potassium chloride in concentrations that exceed recommended limits. - Mixing with medications that are unstable in hyperosmolar environments (e.g., certain antibiotics).

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte disturbances. - Administration alongside catecholamines, which can increase glucose production. - Infusion with blood products that contain citrate, potentially affecting calcium balance.